Day One - Wednesday May 8th
| Time | Topic |
|---|---|
| 9.00am |
Opening Panel Session:
Obamacare and the ACA: the impact on the oncology manufacturers
|
| 10.00am |
Integrate market access across commercial functions
|
| 10.35am |
Coffee
|
| 11.15am |
Understand stakeholder perspectives on quality of care and learn to collaborate for product success
|
| 11.50am |
How biosimilars will affect you and your product strategy
|
| 12.25pm |
Lunch
|
| 1.30pm |
Connect the dots and achieve cross-functional cooperation
|
| 2.05pm |
Oncology medical home as a vehicle for risk and cost reduction
|
| 2.40pm |
What factors determine optimal site of patient care?
|
| 3.15pm |
Coffee
|
| 3.45pm |
Exchanges, ACOs and the impact on oncology care & oncology decision making post-2014
|
| 4.20pm |
The fallacy of emerging models: preserve community oncology by supporting buy and bill
|
| 4.55pm |
Panel Session:
C-Suite pathways panel
|
| 5.45pm |
Networking Drinks & Dinner
|
Day Two - Thursday May 9th
Market Access & Marketing Masterclass
| Time | Topic |
|---|---|
| 9.00am |
Personalized medicine: biomarkers, diagnostics and physician/payer adoption in an ever-changing reimbursement climate
|
| 9.35am |
Work with your stakeholders to achieve market access
|
| 10.10am |
Payer perspective on the value of innovation in an increasingly crowded marketplace
|
| 10.45am |
Coffee
|
| 11.15am |
Deliver a new oncology customer experience: maintain access and relevance to Oncologists even when they're shutting their doors
|
| 11.50am |
Optimizing Rx Value with Dx
|
| 12.25pm |
Lunch
|
| 1.30pm |
Payer perspectives prior to phase 3: endpoints, quality measures and RWE
|
| 2.05pm |
Marketing for targeted therapies
|
| 2.40pm |
Collaborate with diagnostic developers to achieve personalized Marketing
|
| 3.05pm |
Close
|
